The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures.
With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the development of cardiovascular disease. The mechanisms behind the development of metabolic disorders in cancer survivors have not been fully elucidated. However, association studies in the general population have demonstrated correlations between the components of the metabolic syndrome on the one hand and hormonal deficiencies, hypomagnesaemia, and endothelial dysfunction on the other. These latter disorders are regularly reported following curative cancer treatment and could, therefore, be important aetiologic factors in the development of the metabolic syndrome in cancer survivors. This review discusses data on the associations between the metabolic syndrome and treatment-related complications in cancer survivors and possibilities for preventive measures.
D000818:Animals; D002318:Cardiovascular Diseases / Q000097:blood; D004730:Endothelium, Vascular / Q000503:physiopathology; D004967:Estrogens / Q000172:deficiency; D005260:Female; D013006:Growth Hormone / Q000172:deficiency; D006801:Humans; D007333:Insulin Resistance; D008274:Magnesium; D008275:Magnesium Deficiency / Q000150:complications; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology*; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism / Q000628:therapy*; D017741:Survivors; D013739:Testosterone / Q000172:deficiency / Q000627:therapeutic use; D013963:Thyroid Hormones / Q000172:deficiency
D004967:Estrogens; D013963:Thyroid Hormones; D013739:Testosterone; D013006:Growth Hormone; D008274:Magnesium